AM-111 prevents hearing loss from semicircular canal injury in otitis media

Laryngoscope. 2010 Jan;120(1):178-82. doi: 10.1002/lary.20759.


Objectives/hypothesis: Iatrogenic semicircular canal (SC) transection during mastoidectomy for chronic otitis media often leads to profound hearing loss. AM-111, an apoptosis inhibitor, has been shown to mitigate hearing loss resulting from a variety of inner ear injuries. The goal of this study was to determine if round window application of AM-111 following SC transection in the presence of Pseudomonas aeruginosa otitis media (PA-OM) may reduce the associated hearing loss.

Study design: Prospective, randomized, controlled study in an animal model.

Methods: PA-OM was induced bilaterally in 34 guinea pigs. After 3 days, both bullae were opened and the lateral SC of one ear was transected. AM-111 or vehicle was applied topically to the round window of the ear that had undergone SC transection. Hearing was assessed with auditory brainstem responses.

Results: The mean change in hearing thresholds was significantly less in transected ears treated with AM-111 than those receiving vehicle alone when testing with clicks (22.1 dB vs. 35.0 dB; P = .019) and at 4kHz (11.3 dB vs. 40.0 dB; P = .021). A similar trend was shown with 16 kHz tone pips (27.7 dB vs. 41.1 dB; P = .119).

Conclusions: AM-111 prevents hearing loss from SC transection in the guinea pig model of PA-OM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Animals
  • Apoptosis / drug effects*
  • Guinea Pigs
  • Hearing Loss / etiology
  • Hearing Loss / prevention & control*
  • Otitis Media / complications*
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Prospective Studies
  • Pseudomonas Infections / complications
  • Pseudomonas aeruginosa
  • Random Allocation
  • Semicircular Canals / injuries*


  • Peptides
  • D-JNKI-1